ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation

A trial with no phase registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 1500 participants.

Also called NCT05932615

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05932615
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Netherlands, Sweden, Switzerland, United Kingdom (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT05932615. Randomized; no masking; primary purpose treatment. Start 2024-03-15 (actual); primary completion 2027-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation
Acronym
ENVISION
Condition
Aortic Valve Stenosis
Condition
Heart Valve Diseases
Condition
Aortic Valve Disease
Condition
Heart Disease Structural Disorder
Intervention (Device)
Navitor Transcatheter Aortic Valve Implantation (TAVI) System
Intervention (Device)
Any Commercially Available Transcatheter Aortic Valve (CAV) System
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct05932615
Content hash
a335f3d3c0e8cf3526710354d6d1234c7975735305bf680bbfda7a7533d32ab5